Groupe Hospitalier Du Sud Ile De France

The Service de maladies infectieuses et tropicales at Groupe Hospitalier Du Sud Ile De France focuses on severe infections that require intensive care, including bacterial, viral, and fungal pathogens. Clinical studies aim to improve survival and organ function by testing novel antimicrobial strategies and supportive therapies for patients with septic shock, high‑risk pneumonia, and drug‑resistant organisms.

• Severe influenza requiring invasive mechanical ventilation
• ESBL‑producing Enterobacteriaceae infections in ICU
• Septic shock management with adjunctive agents
• Carbapenem‑sparing antibiotic regimens
• Staphylococcal prosthetic joint infection treated by debridement‑antibiotics‑implant retention

These trials seek to refine therapeutic choices, reduce antimicrobial resistance, and enhance recovery for critically ill patients.

Research in the respiratory domain addresses acute lung injury from pneumonia, COVID‑19, and other infections. Studies evaluate anti‑inflammatory agents, plasma‑derived proteins, and optimized ventilatory approaches to shorten ventilation time and improve lung healing.

• Hydroxychloroquine combined with low‑dose corticosteroids for pulmonary sarcoidosis
• Recombinant human plasma gelsolin in moderate‑to‑severe ARDS
• Trimodulin as adjunctive therapy in community‑acquired pneumonia and COVID‑19
• Azithromycin versus clarithromycin for Mycobacterium avium complex lung disease
• Early plasma underdosing of oseltamivir carboxylate in severe influenza

The goal is to reduce respiratory distress, accelerate weaning from ventilators, and lower mortality in high‑risk lung disease patients.

The site conducts trials targeting heart failure, thromboembolic risk, and cardiovascular outcomes in acute settings. Investigations compare continuation versus withdrawal of cardio‑protective drugs and assess novel anticoagulants and heart‑rate modulators to prevent relapse and improve survival.

• Beta‑blocker discontinuation in patients with recovered left ventricular ejection fraction
• Rivaroxaban versus low‑molecular‑weight heparin for VTE prophylaxis after lower‑limb trauma
• Ivabradine for heart‑rate control and 28‑day survival in septic shock
• Aspirin therapy after acute pneumonia to reduce all‑cause mortality
• ctDNA‑guided FOLFOX6m adjuvant treatment to improve disease‑free survival in colon cancer

These studies aim to optimize medication strategies, prevent thrombotic events, and support long‑term cardiovascular health.

A major focus is on systemic vasculitides and autoimmune disorders, where immune modulation can alter disease trajectory. Trials test biologic agents, targeted immunosuppression, and combination therapies to achieve remission and protect vascular integrity.

• Tocilizumab with steroids for giant cell arteritis with cerebrovascular involvement
• Salvage regimens (rituximab + cDMARD, tocilizumab, tofacitinib) for refractory granulomatosis with polyangiitis
• Obinutuzumab for non‑infectious active cryoglobulinemic vasculitis refractory to rituximab
• Secukinumab in Takayasu arteritis to achieve disease remission
• Prednisone plus anticoagulant versus prednisone alone for deep venous thrombosis in Behçet’s syndrome

The purpose is to induce durable remission, prevent vascular complications, and expand therapeutic options for patients with limited treatment responses.

Studies address chronic viral infections, especially hepatitis B in the context of HIV. Innovative antiviral compounds are evaluated for their ability to achieve sustained viral suppression while maintaining antiretroviral efficacy.

• Bepirovirsen for hepatitis B virus virologic response in HIV‑coinfected individuals
• Azithromycin versus clarithromycin for Mycobacterium avium complex pulmonary disease

These trials seek to improve viral control, reduce liver disease progression, and enhance quality of life for co‑infected patients.

The department integrates advanced diagnostic technologies to guide therapeutic decisions in cancer. Research evaluates circulating tumor DNA (ctDNA) monitoring and novel analytical equipment to personalize adjuvant treatments.

• ctDNA‑guided decision making for adjuvant FOLFOX6m in stage II colon carcinoma
• Implementation of new analytical and therapeutic equipment for disease monitoring
• Evaluation of molecular markers to predict treatment response

The aim is to increase disease‑free survival, reduce overtreatment, and establish precision oncology approaches at the site.